UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Low accuracy of FIB-4 test to identify people with diabetes at low risk of advanced fibrosis

Journal of hepatology, 2022-10, Vol.77 (4), p.1219-1221

2022

Volltextzugriff (PDF)

An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary care

Diabetic medicine, 2022-06, Vol.39 (6), p.e14799-n/a

2022

Volltextzugriff (PDF)

Underappreciation of non‐alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis

Internal medicine journal, 2018-02, Vol.48 (2), p.144-151

2018

Volltextzugriff (PDF)

Can paracetamol (acetaminophen) be administered to patients with liver impairment?

British journal of clinical pharmacology, 2016-02, Vol.81 (2), p.210-222

2016

Volltextzugriff (PDF)

Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists

Annals of hepatology, 2023-11, Vol.28 (6), p.101142, Article 101142

2023

Volltextzugriff (PDF)

Improving Medication‐Related Outcomes in Chronic Liver Disease

Hepatology communications, 2020-11, Vol.4 (11), p.1562-1577

2020

Volltextzugriff (PDF)

Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes

BMC health services research, 2022-04, Vol.22 (1), p.487-487, Article 487

2022

Volltextzugriff (PDF)

Poor disease knowledge is associated with higher healthcare service use and costs among patients with cirrhosis: an exploratory study

BMC gastroenterology, 2022-07, Vol.22 (1), p.1-340, Article 340

2022

Volltextzugriff (PDF)

Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations

Expert opinion on drug metabolism & toxicology, 2020-01, Vol.16 (1), p.45-57

2020

Volltextzugriff (PDF)

Managing medicines in alcohol-associated liver disease: a practical review

Australian Prescriber, 2021-06, Vol.44 (3), p.96-106

2021

Volltextzugriff (PDF)

Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis

World journal of gastroenterology : WJG, 2017-10, Vol.23 (40), p.7321-7331

2017

Volltextzugriff (PDF)

Predicting Liver‐Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests

Hepatology communications, 2022-04, Vol.6 (4), p.728-739

2022

Volltextzugriff (PDF)

Collaboration Is Needed to Translate Pharmacology Data Into Better Health Outcomes in Chronic Liver Disease

Hepatology communications, 2021-04, Vol.5 (4), p.715-716

2021

Volltextzugriff (PDF)

Clinically Significant Fibrosis Is Associated With Longitudinal Increases in Fibrosis-4 and Nonalcoholic Fatty Liver Disease Fibrosis Scores

Clinical gastroenterology and hepatology, 2020-03, Vol.18 (3), p.710-718.e4

2020

Volltextzugriff (PDF)

ICD-10-AM codes for cirrhosis and related complications: key performance considerations for population and healthcare studies

BMJ open gastroenterology, 2020-09, Vol.7 (1), p.e000485

2020

Volltextzugriff (PDF)

Towards collaborative management of non‐alcoholic fatty liver disease: a ‘real‐world’ pathway for fibrosis risk assessment in primary care

Internal medicine journal, 2022-10, Vol.52 (10), p.1749-1758

2022

Volltextzugriff (PDF)

Changing Prevalence of Medication Use in People with Cirrhosis: A Retrospective Cohort Study Using Pharmaceutical Benefits Scheme Data

Drugs -- real world outcomes, 2023-12, Vol.10 (4), p.605-618

2023

Volltextzugriff (PDF)

Medication Discrepancies and Regimen Complexity in Decompensated Cirrhosis: Implications for Medication Safety

Pharmaceuticals (Basel, Switzerland), 2021-11, Vol.14 (12), p.1207

2021

Volltextzugriff (PDF)

Longitudinal Change in Simple Scores Identifies Fibrosis Status in People With Nonalcoholic Fatty Liver Disease

Journal of clinical gastroenterology, 2020-08, Vol.54 (7), p.661-662

2020

Volltextzugriff (PDF)

Longitudinal Change in Simple Scores Identifies Fibrosis Status in People With Nonalcoholic Fatty Liver Disease

Journal of clinical gastroenterology, 2020-08, Vol.54 (7), p.661

2020

Volltextzugriff (PDF)

Effectiveness of patient‐oriented education and medication management intervention in people with decompensated cirrhosis

Internal medicine journal, 2020-09, Vol.50 (9), p.1142-1146

2020

Volltextzugriff (PDF)

Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease

Canadian journal of gastroenterology & hepatology, 2017-01, Vol.2017 (2017), p.1-8

2017

Volltextzugriff (PDF)

Patient‐oriented medication education intervention has long‐term benefits for people with decompensated cirrhosis

Hepatology communications, 2022-11, Vol.6 (11), p.3281-3282

2022

Volltextzugriff (PDF)

Optimising care of patients with chronic disease: patient‐oriented education may improve disease knowledge and self‐management

Internal medicine journal, 2017-08, Vol.47 (8), p.952-955

2017

Volltextzugriff (PDF)

Nonalcoholic Fatty Liver Disease: Interface Between Primary Care and Hepatology Clinics

Hepatology communications, 2020-04, Vol.4 (4), p.518-526

2020

Volltextzugriff (PDF)

1 – 25 von 258

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(229)
Mit Volltextzugriff
(205)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(258)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Low accuracy of FIB-4 test to identify people with diabetes at low risk of advanced fibrosis

An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary care

Underappreciation of non‐alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis

Can paracetamol (acetaminophen) be administered to patients with liver impairment?

Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists

Improving Medication‐Related Outcomes in Chronic Liver Disease

Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes

Poor disease knowledge is associated with higher healthcare service use and costs among patients with cirrhosis: an exploratory study

Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations

Managing medicines in alcohol-associated liver disease: a practical review

Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis

Predicting Liver‐Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests

Collaboration Is Needed to Translate Pharmacology Data Into Better Health Outcomes in Chronic Liver Disease

Clinically Significant Fibrosis Is Associated With Longitudinal Increases in Fibrosis-4 and Nonalcoholic Fatty Liver Disease Fibrosis Scores

ICD-10-AM codes for cirrhosis and related complications: key performance considerations for population and healthcare studies

Towards collaborative management of non‐alcoholic fatty liver disease: a ‘real‐world’ pathway for fibrosis risk assessment in primary care

Changing Prevalence of Medication Use in People with Cirrhosis: A Retrospective Cohort Study Using Pharmaceutical Benefits Scheme Data

Medication Discrepancies and Regimen Complexity in Decompensated Cirrhosis: Implications for Medication Safety

Longitudinal Change in Simple Scores Identifies Fibrosis Status in People With Nonalcoholic Fatty Liver Disease

Longitudinal Change in Simple Scores Identifies Fibrosis Status in People With Nonalcoholic Fatty Liver Disease

Effectiveness of patient‐oriented education and medication management intervention in people with decompensated cirrhosis

Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease

Patient‐oriented medication education intervention has long‐term benefits for people with decompensated cirrhosis

Optimising care of patients with chronic disease: patient‐oriented education may improve disease knowledge and self‐management

Nonalcoholic Fatty Liver Disease: Interface Between Primary Care and Hepatology Clinics

Suchergebnisse filtern